Lantern Pharma Stock EBITDA
| LTRN Stock | USD 5.01 0.18 3.73% |
Lantern Pharma fundamentals help investors to digest information that contributes to Lantern Pharma's financial success or failures. It also enables traders to predict the movement of Lantern Stock. The fundamental analysis module provides a way to measure Lantern Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lantern Pharma stock.
Lantern |
Lantern Pharma Company EBITDA Analysis
Lantern Pharma's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Lantern Pharma EBITDA | (15.79 M) |
Most of Lantern Pharma's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lantern Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, Lantern Pharma reported earnings before interest,tax, depreciation and amortization of (15.79 Million). This is 101.8% lower than that of the Biotechnology sector and 115.76% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.4% higher than that of the company.
Lantern EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lantern Pharma's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lantern Pharma could also be used in its relative valuation, which is a method of valuing Lantern Pharma by comparing valuation metrics of similar companies.Lantern Pharma is currently under evaluation in ebitda category among its peers.
Lantern Fundamentals
| Return On Equity | -0.53 | ||||
| Return On Asset | -0.34 | ||||
| Current Valuation | 26.27 M | ||||
| Shares Outstanding | 10.78 M | ||||
| Shares Owned By Insiders | 14.71 % | ||||
| Shares Owned By Institutions | 35.05 % | ||||
| Number Of Shares Shorted | 238.67 K | ||||
| Price To Book | 2.03 X | ||||
| EBITDA | (15.79 M) | ||||
| Net Income | (15.96 M) | ||||
| Cash And Equivalents | 62.15 M | ||||
| Cash Per Share | 5.74 X | ||||
| Total Debt | 234.47 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 12.38 X | ||||
| Book Value Per Share | 2.47 X | ||||
| Cash Flow From Operations | (14.35 M) | ||||
| Short Ratio | 1.53 X | ||||
| Earnings Per Share | (1.78) X | ||||
| Target Price | 20.5 | ||||
| Number Of Employees | 21 | ||||
| Beta | 1.6 | ||||
| Market Capitalization | 54.03 M | ||||
| Total Asset | 43.65 M | ||||
| Retained Earnings | (55.24 M) | ||||
| Working Capital | 40.66 M | ||||
| Net Asset | 43.65 M |
About Lantern Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lantern Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lantern Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lantern Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
When determining whether Lantern Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lantern Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lantern Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lantern Pharma Stock: Check out Lantern Pharma Piotroski F Score and Lantern Pharma Altman Z Score analysis. To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lantern Pharma. If investors know Lantern will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lantern Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Lantern Pharma is measured differently than its book value, which is the value of Lantern that is recorded on the company's balance sheet. Investors also form their own opinion of Lantern Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lantern Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lantern Pharma's market value can be influenced by many factors that don't directly affect Lantern Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lantern Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lantern Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lantern Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.